 FLORHAM PARK, N.J., Dec. 22, 2020 GLOBE NEWSWIRE -- Cellectar Biosciences, Inc. NASDAQ: CLRB, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to offer and sell shares of its common stock and common stock equivalents in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 